Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases

- Steroidal inhibitors clinically useful in prostatic diseases are reviewed.
- 5α-Reductase is an enzyme of interest in benign prostatic hyperplasy.
- CYP17 enzyme is a relevant target in prostatic cancer.
- The 5α-reductase inhibitors finasteride and dutasteride have been clinically used.
- Recently, the CYP17 inhibitor abiraterone acetate reached the market.